First day of trading in Cantargia shares and option rights on Nasdaq First North Stockholm

Today, 17 March 2015, trading begins in Cantargia AB’s (“Cantargia”) shares and option rights of series TO 3 and TO 4 on Nasdaq First North Stockholm.Cantargia AB – developing a new type of cancer treatmentCantargia is developing an antibody-based cancer treatment which attacks mature cancer cells as well as cancer stem cells – the root of the disease. The company has selected and applied for a patent for a product candidate, targeted at IL1RAP, which has a specific and strong bind to leukaemia stem cells and mature cancer cells. In preclinical studies the antibody has been shown to have